Gluten

Gluten: A Comprehensive Reference Article

1. Identity: Names, Sources, and Chemical Nature

1.1 Nomenclature and Chemical Classification

Gluten is a structural protein complex naturally found in certain cereal grains. The term typically refers to the elastic network of a wheat grain's proteins — gliadin and glutenin primarily — which forms readily with the addition of water and, in the case of bread dough, kneading.

Gluten may be defined as the "cohesive, visco-elastic proteinaceous material prepared as a by-product of the isolation of starch from wheat flour."

Gluten proteins can be divided into two main fractions according to their solubility in aqueous alcohols: the soluble gliadins and the insoluble glutenins. Both fractions consist of numerous, partially closely related protein components characterized by high glutamine and proline contents.

1.2 Botanical Sources

The types of grains that contain gluten include all species of wheat (common wheat, durum, spelt, khorasan, emmer, and einkorn), and barley, rye, and some cultivars of oat; moreover, cross-hybrids of any of these cereal grains also contain gluten, for example triticale.

Gluten makes up 75–85% of the total protein in bread wheat. Grains of cereals of the Gramineae family have been a required source of food for millennia. Wheat, rye, and barley are unique among the edible grains because their flours have the protein complex called "gluten" that can be formed into a dough with the rheological properties required for the production of leavened bread.

1.3 Key Protein Subfractions

Wheat gluten proteins make up one of the most complex protein aggregates in nature. Their qualitative and quantitative composition is determined by genetic and environmental factors as well as technological processes. Gluten proteins comprise ω5-, ω1,2-, α-, and γ-gliadins as well as high-molecular-weight glutenin subunits (HMW-GS) and low-molecular-weight (LMW) glutenin subunits.

About 50% of gluten proteins are monomeric gliadins with molecular weights (MWs) from 28,000 to 55,000, while about 15% are present as disulfide-linked oligomeric proteins with MWs between 70,000 and 700,000, called HMW-gliadins. The remaining 35% are disulfide-linked polymeric glutenins with MWs from 700,000 to more than 10 million.

The glutenins, which include both high molecular weight (HMW) glutenin subunits and low molecular weight (LMW) glutenin subunits, comprise an economically important class of wheat seed storage proteins. The apparent molecular weights of the individual HMW glutenin polypeptides or subunits range from 90 to 200 kDa. These subunits crosslink by disulfide bonds among themselves and with LMW glutenin polypeptides to form polymers exceeding one million daltons in molecular weight. HMW glutenins constitute 8–10%, while LMW glutenins constitute 15–20% of the total endosperm protein.

Glutenins and gliadins are recognised as the major wheat storage proteins, constituting about 60–85% of the total grain proteins, and they tend to be rich in asparagine, glutamine, arginine, or proline but very low in nutritionally important amino acids lysine, tryptophan, and methionine.

1.4 Common Forms and Preparations

The past five decades have seen the rise of gluten as a commodity in its own right, through the large-scale industrial separation of wheat starch from gluten, plus the controlled drying of the gluten so as to retain its functional properties. The resulting Vital Dry Gluten is most widely used in bakery products. However, gluten (vital, de-vital, or modified) is finding increasing use as a food ingredient to provide a range of functional properties at a more modest price than competitors such as milk and soy proteins.

Vital wheat gluten is a concentrated wheat protein obtained from wheat flour. It is produced by washing out the starch and other water-soluble components from the flour and then drying the remaining protein fraction. The product is characterised by a very high protein content (about 75–80%) with a high biological value and a specific amino acid composition. Gluten is in the form of a light yellow powder with a neutral taste.

Unlike devitalized gluten, vital wheat gluten retains its viscoelastic properties — meaning it rehydrates quickly and forms the same cohesive, elastic network that gives bread its structure and chew. Vital wheat gluten is also commonly referred to as wheat gluten, gluten flour, or wheat protein.

In industrial and food-service contexts, gluten is used in several distinct forms:

• Vital (undenatured) wheat gluten: Dried powder retaining full viscoelastic function; used in bakery, pasta, and meat-analogue production.
• Devitalized (heat-denatured) gluten: Loses extensibility but retains absorptive properties; used as a functional protein additive in specialized food products.
• Seitan (wheat meat / miànjīn / fu): A versatile, high-protein meat substitute derived from vital wheat gluten created by rinsing wheat flour dough with water to remove the starch and leaving behind a chewy, elastic mass that can be seasoned and cooked to mimic the texture and flavor of meat.
• Hydrolyzed wheat protein: A modified form used in both food products and cosmetics, produced through enzymatic or chemical hydrolysis of gluten.

Thanks to its concentrated vegetable protein content, vital wheat gluten is used in the production of protein bars, protein supplements, shakes and other articles with increased protein content. Other markets for gluten include use as an additive in vegetarian, meat, fish, or poultry products, including those in the pet-food industry; in cereal breakfast; or in soy sauce. Due to its thermoplasticity and good film-forming properties, gluten is also used in non-food markets as adhesives.

2. Historical and Traditional Use

2.1 Ancient Agricultural Origins

Archaeological records reveal that about 10,000 years ago, early agricultural societies in the Fertile Crescent started growing grains such as einkorn and emmer wheat, types of ancient cereals. These grains contained natural proteins, later identified as gluten, which gave flexibility and elasticity to dough.

Gluten, a protein found in wheat, barley, and rye, has been a component of bread for thousands of years, dating back to the domestication of wheat in the Fertile Crescent around 10,000 BCE.

Recent reports show archaeobotanical evidence that the origins of bread date back to 14,400 years ago.

2.2 Ancient Egypt and the Near East

Ancient Egyptians mastered bread-making around 4,000 BCE, using sourdough fermentation that enhanced the gluten network. Their bread was so important it played a role similar to money or power — the texture mattered just as much as the nourishment.

Ancient Egyptians dehulled and milled wheat grains using saddle querns, the most ancient type of quern stones, which were later replaced by rotary querns. Breadmaking and beer production in Egypt are closely related and are considered evidence of a high degree of civilization. Bread was made not only with flour prepared from raw grains, but sometimes also with malt (germinated grains).

2.3 Ancient Grains versus Modern Wheat

Gluten is present in all wheat grains and all can induce coeliac disease in genetically susceptible individuals. Analyses of "ancient" and "modern" wheats show that the protein content of modern bread wheat (Triticum aestivum) has decreased over time while the starch content increased. In addition, it was shown that, compared to bread wheat, ancient wheats contain more protein and gluten and greater contents of many coeliac disease–active epitopes. Consequently, no single wheat type can be recommended as better for reducing the risks of or mitigating the severity of coeliac disease.

While some cultures did eat wheat berries or grind wheat into flour for certain uses, gluten consumption was not nearly as high as it is today. It wasn't until the 19th century that wheat was milled in large quantities and gluten assumed a more prominent place in the diet. As global transportation improved, railroads were built across America, and the industrial revolution progressed, it became easy and inexpensive to mill and distribute wheat flour.

2.4 East Asian Buddhist Traditions

Wheat gluten (mianjin in Chinese) originated in ancient China around the 6th century CE as a vegetarian staple for Buddhist monks and has evolved into a global ingredient in plant-based diets, prized for its neutral base that absorbs seasonings and its role as a soy-free alternative to products like tofu or tempeh.

Its roots trace back to textual references in Chinese agricultural works like the Qimin Yaoshu from 535 CE.

During the 6th century in Imperial China, Buddhist monks developed wheat gluten as a way to offer meat-like textures to non-vegetarian visitors of their monastery. The monks found that by washing a simple wheat dough time and again in fresh water, they were able to rinse out the starches and leave behind the glutenous structure.

The tradition of wheat gluten extended to Japan in the 14th century during the Muromachi period (1336–1573), when Zen Buddhist monks returning from study in China introduced it as fu, an aerated and dried form of gluten. Initially confined to temple kitchens, fu became integral to shōjin ryōri, the ascetic vegetarian cuisine of Zen monasteries, where it mimicked seafood or meat textures in broths and soups while adhering to Buddhist dietary restrictions.

In Vietnam, wheat gluten is called mì căn or mì căng, and is prepared in a similar fashion to Chinese miàn jīn. Along with tofu, it is a part of the Buddhist cuisine of Vietnam.

The term "seitan" was coined in 1961 by George Ohsawa, a Japanese macrobiotic philosopher, combining Japanese words for "made of" (sei) and "protein" (tan).

This form of "wheat meat" made its way to the West during the 18th century through the publication of a treatise on wheat in Italy by Bartolomeo Beccari.

3. Key Constituents and Active Compounds

3.1 Gliadins

Gliadins are mainly monomeric proteins with molecular weights (MWs) around 28,000–55,000 and can be classified according to their different primary structures into the alpha/beta-, gamma-, and omega-type. Disulphide bonds are either absent or present as intrachain crosslinks.

The gliadins are a polymorphic mixture of proteins soluble in 70% alcohol, and can be separated into α-, β-, γ-, and ω-gliadins with a molecular weight range of 30 to 80 kDa.

Generally, it is believed that gliadin controls the viscosity of dough and glutenin controls the elastic or strength properties. The precise balance between viscosity (extensibility) and elasticity (dough strength), or the glutenin to gliadin ratio, is important for bread making.

3.2 Glutenins

The glutenins, which include both high molecular weight (HMW) and low molecular weight (LMW) glutenin subunits, comprise an economically important class of wheat seed storage proteins. The apparent molecular weights of the individual HMW glutenin polypeptides range from 90 to 200 kDa. These subunits crosslink by disulfide bonds among themselves and with LMW glutenin polypeptides to form polymers exceeding one million daltons in molecular weight.

In wheat, HMW glutenins are encoded at the Glu-1 loci on the long arms of the group 1 chromosomes. Each locus consists of two separate genes, encoding an x-type and a y-type subunit, respectively.

3.3 The Gluten Network and Viscoelastic Mechanism

Intrachain disulfide bonds, present in all types except ω-gliadins, stabilize the three-dimensional structure. The gluten network represents a two-component system in which gliadins can be seen as a "plasticizer" or "solvent" for glutenins. An appropriate ratio of both fractions is therefore essential to impart the viscoelastic dough properties required to achieve a high-quality end product. A high ratio of gliadins to glutenins leads to less viscous and more extensible (soft) doughs, whereas a low ratio generates highly viscous and less extensible (strong) doughs.

3.4 Immunologically Active Epitopes

In addition to their role in dough quality, gluten proteins can affect health in genetically susceptible individuals. Among the different gluten subunits, the α-gliadins are considered the most immunogenic, while γ-gliadins and glutenins are much less responsible for gluten intolerance.

The overall content and relative proportions of gluten protein types vary considerably depending on different genetic and environmental factors and mutual interactions. Environmental and crop management factors such as soil type, weather conditions, atmospheric CO₂ concentration, diseases, and fertilization with nitrogen, sulfur, phosphorus, potassium, and other minerals affect wheat gluten protein composition.

4. Scientific Evidence by Area of Use and Health Condition

4.1 Celiac Disease (Coeliac Disease)

Overview and Prevalence

Celiac disease is an autoimmune disorder triggered by an immune-mediated response of the small intestine to dietary gluten, which is a protein found in wheat, barley, and rye. Although traditionally viewed as a gastrointestinal condition primarily associated with malabsorption, it is now more accurately classified as an autoimmune disorder with systemic manifestations.

Celiac disease is not a rare disorder like previously thought, with a global prevalence around 1%. The reason for its under-recognition is mainly referable to the fact that about half of affected people do not have the classic gastrointestinal symptoms, but they present nonspecific manifestations of nutritional deficiency or have no symptoms at all.

Studies of stored serum show that the prevalence of celiac disease has increased fourfold to fivefold over the past 50 years, and the reason for this rise is unknown, although it may relate to aspects of the hygiene hypothesis.

Pathophysiology

The erroneous adaptive immune response — the consequence of a highly specific interplay between selected gluten peptides and major histocompatibility complex class II HLA-DQ2/8–antigen restricted T cells — plays a paramount role in celiac disease pathogenesis. Dependent on the post-translational deamidation of gluten peptides by transglutaminase 2 (TG2), this interplay is influenced by the initial imprinting of the innate immune system through IL-15 upregulation that promotes the CD4+ T cell adaptive immune response.

Gluten or gliadin crosses the epithelial cells, and after deamidation by transglutaminase-2 (TG2), they become easier to be recognized by antigen presenting cells (APCs) expressing HLA-DQ2/8. CD4+ T cells activate B cells to differentiate into plasma cells with secretion of antibodies against gluten, TG2, and deamidated polypeptides complex.

The contact of CD4+ T cells in the lamina propria with gluten induces their activation and proliferation, with production of proinflammatory cytokines, metalloproteases, and keratinocyte growth factor by stromal cells, which induces cryptal hyperplasia and villous blunting.

Intestinal Damage and Clinical Manifestations

This damage is evidenced by villous atrophy, crypt hyperplasia, and infiltration of the lamina propria by immune cells, which in turn leads to malabsorption of essential nutrients, including micronutrients, fat-soluble vitamins, iron, vitamin B12, and folate. Typical gastrointestinal symptoms include diarrhea, abdominal discomfort, bloating, and constipation.

The disease can occur at any age, with a variety of symptoms/manifestations. This multifaceted clinical presentation leads to several phenotypes, i.e., gastrointestinal, extraintestinal, subclinical, potential, seronegative, non-responsive, and refractory.

Diagnosis

The gold standard for diagnosis is intestinal mucosal biopsy, combined with serological and genetic tests. Disease-specific antibodies can aid in selecting patients for a small intestinal biopsy. However, in selected patients, serology can be sufficient to confirm the diagnosis and a biopsy is not needed.

Evidence strength: The pathophysiological model for celiac disease is well-established with strong clinical and mechanistic evidence from multiple controlled studies, systematic reviews, and decades of international research. The gluten-free diet is the only proven, guideline-endorsed treatment.

4.2 Non-Celiac Gluten Sensitivity (NCGS)

Non-celiac gluten sensitivity (NCGS) is a clinical entity characterized by intestinal and/or extra-intestinal symptoms related to the ingestion of gluten in individuals that are not affected by either celiac disease (CD) or wheat allergy (WA). Since we do not have specific biomarkers for NCGS, the diagnosis is based on the evidence of a clear relationship between the ingestion of gluten (re-challenge) and clinical symptoms, after a remission during the gluten-free diet (GFD).

Non-coeliac gluten sensitivity (NCGS) remains a highly contested clinical entity, with uncertainty about its existence. NCGS is characterised by intestinal and extraintestinal symptoms related to gluten-containing foods, occurring in the absence of coeliac disease or wheat allergy. However, the diagnostic criteria and underlying mechanisms for this condition remain poorly understood.

The typical phenotype of NCGS is most observed in individuals with a mean age of 38 years, and studies report that 72–84% of cases are in women.

Clinical Challenge Evidence

Eleven studies were included in one meta-analysis. There was considerable heterogeneity related to different sample size, type, and amount of gluten administered, duration of challenge, and different type of placebo. The overall pooled percentage of patients with a diagnosis of NCGS relapsing after a gluten challenge was 30%, ranging between 7 and 77%. The meta-analysis showed a not significant relative risk (RR) of relapse after gluten challenge as compared to placebo (RR = 0.4; 95% CI = −0.15–0.9; p = 0.16).

The overall pooled percentage of patients with a diagnosis of NCGS relapsing after a gluten challenge performed according to the recent Salerno criteria was significantly higher as compared to the percentage of patients relapsing after placebo (40 vs. 24%; p = 0.003), with a significant RR of relapse after gluten challenge as compared to placebo (RR = 2.8; 95% CI = 1.5–5.5; p = 0.002). The prevalence of NCGS after gluten re-challenge is low, and the percentage of relapse after a gluten or a placebo challenge is similar in some studies.

Pathophysiological Mechanisms in NCGS

The pathophysiology of NCGS is unclear. Increased permeability of the small intestine was noted in two studies but not in a third. Gut mucosal immune activation seems to be present, with increased CD3-positive intraepithelial lymphocytes compared with patients with celiac disease who are maintained on a gluten-free diet, evidence of an adaptive immune response, and increased interferon γ response to a gluten challenge. Interest has recently developed in the non-gluten components of wheat, including the amylase trypsin inhibitors, which seem to activate the innate immune system and have been suggested to have a role in both celiac disease and NCGS.

Evidence strength: NCGS as a distinct entity remains controversial. Some well-designed re-challenge studies show genuine gluten-specific effects, while others show significant placebo responses. Current evidence is preliminary and mixed; no specific biomarker has been validated for diagnosis.

4.3 IgE-Mediated Wheat Allergy

Wheat allergy consists of IgE- and non-IgE-mediated reactions, driven by Th2-cells directing eosinophil and basophil responses.

IgE-mediated wheat allergy can take on various forms, including childhood food allergy to wheat, wheat-dependent exercise-induced anaphylaxis in young adults, baker's respiratory allergy/asthma in workers exposed to wheat flour inhalation, and contact urticaria that is caused by hydrolyzed wheat proteins in cosmetics.

Major wheat protein allergens are classified into two main categories: water/salt-soluble proteins (e.g., alpha-amylase inhibitors, lipid transfer proteins, and avenin-like proteins) and alcohol/diluted acid-soluble proteins (e.g., gliadins and glutenins). The most allergenic wheat proteins responsible for IgE-mediated wheat allergy are gliadins, particularly omega (ω)-5-gliadin, and glutenins. In cases of wheat-dependent exercise-induced anaphylaxis (WDEIA), ω-5-gliadin and LTP have been identified as the major allergens involved.

Several studies have shown that sensitization particularly to omega-5 gliadin is associated with challenge-proven wheat allergy. Moreover, recent data imply that gliadin-positive patients are more likely to have severe reactions after wheat ingestion. A well-characterized severe clinical entity is also wheat-dependent, exercise-induced anaphylaxis, in which sensitization to omega-5 gliadin is a prerequisite.

IgE-mediated wheat allergy is not only a significant food allergy but also a notable occupational wheat allergy in bakers, known as bakers' asthma. It stands as the most common occupational allergy in various countries, impacting a percentage as high as 40% of bakers in the UK.

Evidence strength: IgE-mediated wheat allergy is well-established with robust immunological and clinical diagnostic evidence. Molecular allergology has enabled precise identification of individual allergens involved.

4.4 Dermatitis Herpetiformis

Gluten-related disorders include celiac disease and non-celiac gluten sensitivity, presenting with both intestinal and extraintestinal symptoms, including skin manifestations. Besides the well-known association between celiac disease and dermatitis herpetiformis, considered the cutaneous manifestation of celiac disease, other dermatoses have also been associated with gluten-related disorders.

Dermatitis herpetiformis, the cutaneous manifestation of celiac disease, is confirmed via direct immunofluorescence of perilesional skin.

The production of anti-transglutaminase 3 antibodies in patients with dermatitis herpetiformis is gluten-dependent, which substantiates the link to a gluten-specific T-cell population. In dermatitis herpetiformis, IgA deposits of transglutaminase 3 accumulate in the periphery of blood vessels at sites where, in health, the respective proteins are absent.

Evidence strength: Strong clinical evidence from biopsy series and immunofluorescence studies. Treatment with a strict gluten-free diet is well-established as effective in inducing remission.

4.5 Neurological Manifestations: Gluten Ataxia and Gluten Neuropathy

Celiac disease is a complex multi-organ disease with a high prevalence of extra-intestinal involvement, including neurological and psychiatric manifestations, such as cerebellar ataxia, peripheral neuropathy, epilepsy, headache, cognitive impairment, and depression. However, the mechanisms behind the neurological involvement in celiac disease remain controversial. Recent evidence shows these can be related to gluten-mediated pathogenesis, including antibody cross-reaction, deposition of immune complex, direct neurotoxicity, and in severe cases, vitamins or nutrients deficiency.

Gluten-related disorders are a group of immune-mediated diseases that are triggered and progress in response to gluten consumption. Whilst gluten sensitivity is most commonly associated with coeliac disease, the manifestations of gluten-related disorders extend outside of the gastrointestinal tract and can affect the skin, causing dermatitis herpetiformis, and the CNS, leading to a diverse range of neurological dysfunction including gluten ataxia, sensory ganglionopathy, sensorimotor axonal neuropathy, encephalopathy, myopathy, myelopathy, and brain white matter abnormalities.

Patients with celiac disease are at an increased risk of several neurological manifestations, frequently peripheral neuropathy and gluten ataxia. A systematic literature review of the most commonly reported neurological manifestations (neuropathy and ataxia) associated with celiac disease was performed, searching MEDLINE, Embase, the Cochrane Library, and conference proceedings from January 2007 through September 2018. Sixteen studies were included describing the risk of gluten neuropathy and/or gluten ataxia in patients with celiac disease. Gluten neuropathy was a neurological manifestation in celiac disease in up to 39% of cases across 13 studies.

Antibodies against transglutaminase 6, primarily a brain-expressed transglutaminase, have been shown to be present in patients with gluten ataxia. Gluten ataxia, a rare neurological disorder, may show cerebellar atrophy and respond best to early initiation of a gluten-free diet.

Evidence strength: Evidence for gluten ataxia and gluten neuropathy as distinct clinical entities is growing but largely derived from observational studies, case series, and cohort studies. Randomized controlled trial data are limited. Mechanistic studies support a role for TG6 antibodies and perivascular inflammation in gluten ataxia pathogenesis.

4.6 Gluten-Free Diet in Non-Celiac Populations

There is little scientific evidence that a gluten-free diet has health benefits for anyone without celiac disease or a nonceliac gluten sensitivity. A gluten-free diet is essential for those with celiac disease. However, there is little evidence to support its use in people without celiac disease, and it may increase the risk of nutritional deficiencies.

Although convincing evidence is available to support the benefits of a gluten-free diet for certain patient populations without a gluten-related disease (especially patients with IBS and NCGS), the data are conflicting and not definitive. It appears that most individuals who participate in a gluten-free diet do not have a physiologic requirement for the diet and likely do not derive substantial benefit. Existing evidence for potential harms of a gluten-free diet include possible nutritional deficiencies, financial costs, and negative psychosocial implications.

Evidence strength: Weak to absent evidence for benefit in the general population. The evidence for harm (nutritional deficiency risk) is moderate and documented in systematic reviews.

5. Body Systems and Health Areas Associated with Gluten

5.1 Gastrointestinal System

The gastrointestinal tract is the primary system affected by all gluten-related disorders. Villous atrophy, crypt hyperplasia, and infiltration of the lamina propria by immune cells lead to malabsorption of essential nutrients, including micronutrients, fat-soluble vitamins, iron, vitamin B12, and folate. Gastrointestinal symptoms may include abdominal pain, diarrhea or constipation, bloating, and excessive gas.

5.2 Immune System

Gluten activates both innate and adaptive immune pathways in susceptible individuals. The pathophysiology of celiac disease involves both the innate and adaptive immune response to dietary gluten. The HLA-DQ2 and HLA-DQ8 genetic variants are the primary immunological susceptibility factors, conditioning how gluten peptides are presented to T cells.

5.3 Musculoskeletal System

With longer-standing disease, patients may present with profound vitamin D deficiency resulting in rickets or hypocalcemia and tetany, or coagulopathy secondary to vitamin K deficiency. The clinical presentation of celiac disease varies broadly and may include an array of intestinal symptoms and extra-intestinal manifestations, such as iron-deficiency anemia, osteoporosis, dermatitis herpetiformis, and neurologic disorders.

5.4 Central and Peripheral Nervous System

Known neurological manifestations of celiac disease include epilepsy with or without occipital calcification, attention deficit hyperactivity disorder and ataxia, headache, neuropathies, and behavior disorders. Celiac disease has been linked to a variety of neurological conditions including epilepsy, cerebellar ataxia, chronic neuropathies, myoclonic ataxia, progressive leukoencephalopathy, and dementia.

5.5 Dermatological System

Gluten-related disorders present with both intestinal and extraintestinal symptoms, including skin manifestations. Dermatitis herpetiformis is considered the cutaneous manifestation of celiac disease, and other dermatoses have been associated with gluten-related disorders.

5.6 Hematological System

Anemia secondary to iron and/or folate deficiency is also observed in celiac disease. Iron deficiency anemia is the most common extra-digestive manifestation of celiac disease, affecting approximately 20% of patients.

5.7 Reproductive and Endocrine System

Clinical features of celiac disease are diverse and include gastrointestinal symptoms, metabolic bone disease, infertility, and many other manifestations. Extraintestinal manifestations might include failure to thrive, stunted growth, delayed puberty, iron deficiency anemia, arthritis, arthralgia, dental enamel defects, elevated liver enzymes, decreased bone mineralization, recurrent mouth ulcers, amenorrhea, dermatitis herpetiformis, irritability, chronic fatigue, depression, and anxiety.

6. Dosage Forms and Dosages Reported in Studies

Gluten is not used as a traditional standardized dietary supplement with an established dose range in the same manner as botanicals or isolated micronutrients. Rather, its dosage in clinical research has been operationalized in terms of daily dietary challenge amounts or gluten-free threshold values:

• Gluten challenge in NCGS re-challenge studies: Studies showed considerable heterogeneity related to different sample size, type, and amount of gluten administered, and duration of challenge. The amounts of gluten used in re-challenge protocols vary substantially across published studies.
• Vital wheat gluten as a food/supplement ingredient: The product is characterised by a very high protein content (about 75–80%). When used as a protein supplement, doses are governed by product labeling and individual dietary protein goals, not clinical trial standardization.
• Threshold for celiac disease harm: Regulatory bodies such as the Codex Alimentarius have established a threshold of 20 ppm (20 mg/kg) as the maximum permissible gluten level in foods labeled "gluten-free," reflecting the level at which the vast majority of patients with celiac disease tolerate exposure without measurable intestinal damage. This threshold is used across the EU, the US FDA, and most international standards, though specific clinical threshold data from individual trials vary.
• Seitan as a food source: Seitan is a versatile, high-protein meat substitute derived from vital wheat gluten; it is consumed in quantities typical of a protein-containing meal component, not a standardized supplement dose.

No universal therapeutic dosage recommendation exists for gluten as a dietary supplement, as its clinical relevance is primarily framed by restriction (gluten-free diet) rather than supplementation for the general population.

7. Safety Considerations and Drug/Nutrient Interactions

7.1 Celiac Disease: Risk of Non-Adherence

Non-compliance with the gluten-free diet can exacerbate symptoms, lead to further intestinal damage, and significantly increase the risk of certain cancers. For instance, the risk of small intestinal adenocarcinoma is 4–10 times higher in individuals with celiac disease compared to healthy individuals, while esophageal cancer, melanoma, and non-Hodgkin's lymphoma also show elevated risks, with approximately 2–3% of celiac disease patients being affected.

7.2 Nutritional Deficiencies on a Gluten-Free Diet

Inadequate intakes of iron, folate, calcium, selenium, magnesium, zinc, niacin, thiamine, and riboflavin, as well as vitamins A and D, were reported in celiac disease patients following a gluten-free diet.

Despite 10 years on the diet and evidence of mucosal recovery, the total plasma homocysteine levels of celiac disease patients were still higher than average, reflecting ongoing deficiencies in folate, vitamin B6, and vitamin B12.

Celiac disease patients have an increased risk of vitamin D and E deficiencies compared with non-celiac disease controls. Celiac disease patients on a gluten-free diet had a decreased risk of vitamin D, B12, E, calcium, and iron deficiencies compared with untreated celiac disease. NCGS patients had an increased risk of vitamin B12, folate, and iron deficiency compared to controls. The overall quality of evidence was rated very low.

Gluten-free products are normally made with starches and/or refined flours characterized by a low content of fiber. Furthermore, studies indicate that gluten-free products usually have a higher carbohydrate and fat content than their gluten-containing counterparts, and gluten-free products are particularly high in saturated fatty acids.

7.3 Risk in the General Population Adopting Gluten-Free Diet

A review of existing data shows that there are detrimental effects to going gluten free, including loss of dietary fiber, deficiencies in dietary minerals and vitamins, and potential heavy metal exposure.

Media and celebrity endorsements of the gluten-free diet for weight loss have stimulated public interest and driven gluten-free market sales. Empirical evidence confirming the diet's effects on weight, however, is still unclear.

7.4 IgE-Mediated Allergy and Anaphylaxis Risk

In IgE-mediated wheat allergy, patients tend to have severe anaphylactic reactions when compared with reactions from other kinds of food such as cow milk and eggs. IgE-mediated wheat allergy is an emerging problem worldwide, particularly prevalent in Northern Europe and parts of Asia. Another unique manifestation, wheat-dependent exercise-induced anaphylaxis (WDEIA), has increasingly been reported in recent decades.

7.5 Labeling and Cross-Contamination

The cornerstone of treatment for all gluten-associated disorders is a gluten-free diet, although the degree of strictness and duration vary. Lifelong adherence is essential for celiac disease and dermatitis herpetiformis, while management of NCGS and gluten ataxia is more individualized. Adherence challenges include dietary cost, cross-contamination, and lifestyle limitations.

7.6 Autoimmune Co-morbidities

Clinical presentation of celiac disease is diverse and there is an increased risk of autoimmune co-morbidities. Recent genetic studies have revealed that celiac disease and other autoimmune diseases share common genetic loci, despite their phenotypic differences.

References

• Wieser et al. (2023). Chemistry of wheat gluten proteins: Qualitative composition. Cereal Chemistry, 100, 23–35.
• Wieser et al. (2023). Chemistry of wheat gluten proteins: Quantitative composition. Cereal Chemistry, 100, 36–55.
• Wieser H. (2007). Chemistry of gluten proteins. Food Microbiology, 24, 115–119. PubMed.
• Gluten. Wikipedia.
• Shewry et al. (2022). Do ancient wheats contain less gluten than modern bread wheat, in favour of better health? PMC / Nutrition Bulletin.
• Murakami S. (2019). Recent practical researches in the development of gluten-free breads. npj Science of Food.
• Goyal A, et al. (2024). Advances in understanding and managing celiac disease: Pathophysiology and treatment strategies. PubMed.
• Caio G, et al. (2019). Celiac disease: a comprehensive current review. PMC / BMC Medicine.
• Lundin KEA & Wijmenga C. (2015). Celiac disease and non-celiac gluten sensitivity. PMC / BMJ.
• Celiac Disease. StatPearls. NCBI Bookshelf (NIH).
• Tovoli F, et al. (2015). Celiac disease: From pathophysiology to treatment. PubMed.
• Celiac disease: an overview from pathophysiology to treatment. PubMed.
• Molina-Infante J, et al. (2017). Re-challenge Studies in Non-celiac Gluten Sensitivity: A Systematic Review and Meta-Analysis. PMC / Frontiers in Physiology.
• Non-coeliac gluten sensitivity (Review). The Lancet, 2025.
• Celiac disease, non-celiac wheat sensitivity, wheat allergy – clinical and diagnostic aspects. Seminars in Immunopathology, 2025.
• Preda M, et al. (2024). Allergenic Biomarkers in the Molecular Diagnosis of IgE-Mediated Wheat Allergy. International Journal of Molecular Sciences.
• Molecular Diagnosis to IgE-mediated Wheat Allergy and WDEIA. Clinical Reviews in Allergy & Immunology, 2025.
• Bagnato G, et al. (2022). Celiac Disease and Neurological Manifestations: From Gluten to Neuroinflammation. PMC / Nutrients.
• Croall I, et al. (2019). Neurological Manifestations of Neuropathy and Ataxia in Celiac Disease: A Systematic Review. PMC / Nutrients.
• Niland B & Cash BD. (2018). Health Benefits and Adverse Effects of a Gluten-Free Diet in Non–Celiac Disease Patients. PMC / Gastroenterology & Hepatology.
• A Gluten-Free Diet, Not an Appropriate Choice without a Medical Diagnosis. PMC / Nutrients, 2019.
• Nutritional quality and costs of gluten-free products. PMC / Food & Nutrition Research, 2021.
• A Review on the Gluten-Free Diet: Technological and Nutritional Challenges. PMC / Nutrients, 2018.
• Micronutrient Deficiencies Associated with a Gluten-Free Diet in Patients with Celiac Disease and NCWS: A Systematic Review and Meta-Analysis. PMC / Nutrients, 2025.
• Impact of a Gluten-Free Diet in Adults With Celiac Disease: Nutritional Deficiencies and Challenges. PMC, 2025.
• Day L, et al. (2006). Wheat-gluten uses and industry needs. Trends in Food Science & Technology, 17, 82–90.
• Seitan. Wikipedia.
• Recent Advances in Gluten-Related Disorders. PMC / International Journal of Molecular Sciences, 2025.
• Gluten-Associated Medical Problems. StatPearls. NCBI Bookshelf (NIH).
• Cerebellar degeneration in gluten ataxia is linked to microglial activation. PMC, 2024.
• Celiac Disease: Pathophysiology, Clinical Manifestations and Associated Autoimmune Conditions. PMC.